At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 341 enrolled
Drug / intervention
Nivolumab +10 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Bevacizumab, and 9 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 341 participants across 133 sites.
Detailed Summary
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionApr 2020
TodayJul 2026
First PostedOct 12, 2015
Enrollment StartNov 23, 2015
Primary CompletionApr 15, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.7 years ago
Interventions
Nivolumabdrug
Bevacizumabdrug
Pemetrexeddrug
Best Supportive Careother
Palliative radiation, palliative surgery and/or other best supportive care treatments
nab-Paclitaxeldrug
Paclitaxeldrug
Docetaxeldrug
Gemcitabinedrug
Erlotinibdrug
Crizotinibdrug
Carboplatindrug